Disc Medicine, Inc. (NASDAQ:IRON – Get Free Report) saw a significant drop in short interest in June. As of June 30th, there was short interest totalling 1,580,000 shares, a drop of 21.0% from the June 15th total of 2,000,000 shares. Based on an average trading volume of 410,900 shares, the short-interest ratio is presently 3.8 days. Currently, 9.8% of the company’s stock are sold short.
Disc Medicine Price Performance
Shares of IRON stock opened at $49.23 on Tuesday. Disc Medicine has a 1 year low of $25.60 and a 1 year high of $77.60. The firm has a fifty day moving average price of $39.03 and a 200-day moving average price of $49.21. The company has a market cap of $1.22 billion, a price-to-earnings ratio of -14.57 and a beta of 0.57.
Disc Medicine (NASDAQ:IRON – Get Free Report) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.09). Equities research analysts expect that Disc Medicine will post -4.47 EPS for the current year.
Analysts Set New Price Targets
View Our Latest Stock Analysis on IRON
Institutional Investors Weigh In On Disc Medicine
A number of hedge funds have recently modified their holdings of IRON. Strs Ohio grew its position in shares of Disc Medicine by 66.7% during the 4th quarter. Strs Ohio now owns 1,000 shares of the company’s stock valued at $57,000 after acquiring an additional 400 shares during the period. AJOVista LLC purchased a new position in shares of Disc Medicine during the 4th quarter valued at $63,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Disc Medicine during the 4th quarter valued at $161,000. SG Americas Securities LLC lifted its stake in shares of Disc Medicine by 44.2% during the 2nd quarter. SG Americas Securities LLC now owns 4,071 shares of the company’s stock valued at $183,000 after buying an additional 1,247 shares in the last quarter. Finally, ProShare Advisors LLC purchased a new position in shares of Disc Medicine during the 1st quarter valued at $211,000. Institutional investors own 83.70% of the company’s stock.
About Disc Medicine
Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Further Reading
- Five stocks we like better than Disc Medicine
- ESG Stocks, What Investors Should Know
- Automaker’s Bold Move to an EV Future: Is It Time to Buy Stock?
- What is the Shanghai Stock Exchange Composite Index?
- Massive Breakout: This ETF Signals Big Gains for Small-Cap Stocks
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Major Gaming Stock to Watch: Why It’s a Safe Bet Now
Receive News & Ratings for Disc Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Disc Medicine and related companies with MarketBeat.com's FREE daily email newsletter.